Profiles

Profiles published here have completed one of the QIBA Profile Stages of development and been approved by their Biomarker Committee.

Profiles may be of use at any Stage.

Stage 3: Clinically Feasible (formerly Technically Confirmed) Profiles

• CT Atherosclerosis Biomarkers, Clinically Feasible Profile: Maintenance draft. June, 2024  DOI:10.1148/QIBA/202406
  • CT Atherosclerosis Biomarkers, Clinically Feasible Profile. March 28, 2023   DOI:10.1148/QIBA/20230328

• CT Small Lung Nodule Volume Assessment and Monitoring in Low Dose Screening, Clinically Feasible Profile. December 19, 2023   DOI:10.1148/QIBA/20231219

• CT Tumor Volume Change for Advanced Disease, Clinically Feasible Streamlined Profile including Conformance Checklists. July 21, 2022   DOI:10.1148/QIBA/20220721

• MR Diffusion-Weighted Imaging (DWI) of the Apparent Diffusion Coefficient (ADC), Clinically Feasible Profile. December 15, 2022   DOI:10.1148/QIBA/20221215

• MR Elastography of the Liver, Clinically Feasible Profile: Maintenance draft. November 7, 2023  DOI:10.1148/QIBA/20231107
  • MR Elastography of the Liver, Clinically Feasible Profile. February 2, 2022.

• PET Amyloid, Clinically Feasible Profile. June 3, 2022.

• PET/CT FDG SUV for Response to Cancer Therapy, v1.14, Clinically Feasible Profile containing updated checklist. June 15, 2023   DOI:10.1148/QIBA/20230615
• PET/CT FDG SUV for Response to Cancer Therapy, v1.13, Clinically Feasible Profile. November 18, 2016.

• UPICT Protocol - Oncology FDG-PET CT v2.0. December, 2014.

• US Shear Wave Speed for Liver Fibrosis, Clinically Feasible Profile. January 15, 2024  DOI:10.1148/QIBA/20240115

• Checklists - US SWS Appendix E. December 28, 2023
• US SWS Checklist for Clinically Feasible Site Assessment. January 26, 2023

Stage 2: Consensus Profiles

• CT Lung Density 2020-09-04 (Contains Conformance Checklists, Appendix B) 2020-10-23

• Protocols - Appendix E:CT Lung Density 2019-06-26

• MR DCE Quantification (V.1) 2012-08-08

• MR Dynamic Contrast Susceptibility 2020-10-22

• MR MSK Cartilage for Joint Disease 2021-09-25

• SPECT Ioflupane for Neurodegenerative Disease 2017-06-26

• SPECT Ioflupane for Neurodegenerative Disease 2019-10-15

• Checklists - SPECT Ioflupane

• SPECT-CT: Estimating the Concentration of 99mTc Based Imaging Biomarkers in Large and Small Volumes of Interest Profile 2019-10-21

• US Volume Blood Flow Profile, Consensus version 2024-01-05

• MRI-Based Proton Density Fat Fraction (PDFF) of the Liver, Consensus Profile: Maintenance draft. June 19, 2024
  • MRI-Based Proton Density Fat Fraction (PDFF) of the Liver, Consensus Profile. December 4, 2023

• MR DCE-MRI Quantification (DCEMRI-Q) (V.2) 2023-12-06

Stage 1: Public Comment Profiles

• fMRI for Sensorimotor Mapping 2017-06-19 (comments closed on December 31, 2017)

Comment Resolutions are posted for Past Public Comments and Past Technical Confirmations.

Tools to aid Biomarker Committees in collating these comments:

• {Public Comment Resolution} - Editor collates all comments into a resolution spreadsheet (see Google Sheet template)
• {Site responses for Stage 3} - Field Test Leader collates all Feedback comments into a Feedback Resolution spreadsheet

QIBA Profiles and Clinical Applications

Format for Citing Profiles

Cite QIBA Profile documents as:

Specific QIBA Biomarker Committee. Specific Profile Title, Quantitative Imaging Biomarkers Alliance. Profile Stage. Date. Available from: URL

Example:

QIBA MR Biomarker Committee. MR Elastography of the Liver, Quantitative Imaging Biomarkers Alliance. Profile Stage: Consensus. June 6, 2019. Available from: http://qibawiki.rsna.org/index.php/Profiles

Statements of Endorsement

• Industry
• Clinical Sites
• Additional letters of support can be found here

See Also

• How to use QIBA Profiles
• Biomarker Committee pages may also have links to DRAFT Profile documents for the next Stage.
• Profile Conformance describes how sites and products claim conformance to a Profile.
• QIBA Profile Template shows the structure, rationale and content of a Profile (show "All Markup" to see guidance in the Word comments)

• Work Product for Review